Mavrilimumab is a human MAB for the treatment of rheumatoid arthritis. It targets the GM-CSF receptor-alpha. More at: http://en.wikipedia.org/wiki/Mavrilimumab
There have been two studies on mavrilimumab at the EULAR 2014 Meeting in Paris.
M. Sleeman and colleagues presented: “MAVRILIMUMAB REDUCES IL-17A AND IL-17F PRODUCTION IN BIOMAP HUMAN PRIMARY CELL SYSTEMS MODELING T CELL-DEPENDENT B CELL ACTIVATION”.Conclusions: “In an in vitro human primary cell model of T cell dependent B cell activation, mavrilimumab inhibited production of soluble cytokines including IL-17A and IL-17F that are induced by endogenous release of GMCSF in the system. As TH17 biology has been implicated in the pathogenesis of RA (Gaffen, 2009) these data suggest that mavrilimumab could impact IL-17 production from pathogenic T cells in the rheumatic joint.”
[SAT0260] W. White and colleagues looked at: “BIOMARKERS ASSOCIATED WITH RHEUMATOID ARTHRITIS DISEASE ACTIVITY INCLUDING JOINT DAMAGE CORRELATE WITH CHANGES IN CLINICAL RESPONSE IN SUBJECTS TREATED WITH MAVRILIMUMAB AT DOSES ABOVE 10 MG”.Conclusions: “Promising results of mavrilimumab support further clinical development at doses greater than 10 mg. Mechanistically, the drug suppressed both acute phase and inflammatory blood markers. Tracking of disease activity by MBDA showed a clear biomarker-based dose-response relationship. The association of MBSD decline with radiographic damage will be assessed in an on-going phase 2b study.”
Compared to the three studien presented the the ACR 2013 Meeting in San Diego this is a step backwards, no matter how interesting the studies themselves might be. Still no phase 3 study with stressable data on radiographic progression. So it means for us waiting longer to see, if mavrilimumab matured into a usable drug.